Leiters, a trusted FDA-registered 503B outsourcing provider of high-quality ophthalmology and hospital-based services, has entered into a national sales and marketing agreement with Mobius Therapeutics™. Through the agreement, Leiters will be able to supply Mitosol®, the only FDA-approved formulation of mitomycin-c bearing an ophthalmic indication. The collaboration will ensure Leiters’ ophthalmic customers will have access to the high-quality medicines they need for their patients.
Mitosol® (mitomycin for solution) 0.2mg/vial is provided as part of a Kit for Ophthalmic Use. The kit contains a 0.2 mg vial of mitomycin-c along with accessories allowing for safe, convenient, and compliant acquisition, storage and handling of mitomycin-c.
This post is related to:Admixture Compounding Services (503B Outsourcing Facilities)